Immunosignatures associated with TP53 status and co-mutations classify prognostically head and neck cancer patients
Abstract Background Immune checkpoint inhibitors (ICIs) are a therapeutic strategy for various cancers although only a subset of patients respond to the therapy. Identifying patients more prone to respond to ICIs may increase the therapeutic benefit and allow studying new approaches for resistant pa...
Main Authors: | Andrea Sacconi, Paola Muti, Claudio Pulito, Giulia Urbani, Matteo Allegretti, Raul Pellini, Nikolay Mehterov, Uri Ben-David, Sabrina Strano, Paolo Bossi, Giovanni Blandino |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2023-11-01
|
Series: | Molecular Cancer |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12943-023-01905-9 |
Similar Items
-
Combined TP53 status in tumor-free resection margins and circulating microRNA profiling predicts the risk of locoregional recurrence in head and neck cancer
by: Federica Ganci, et al.
Published: (2024-03-01) -
Exosomal microRNAs Targeting TP53 Gene as Promising Prognostic Markers for Head and Neck Squamous Cell Carcinoma
by: Vijayashree Priyadharsini Jayaseelan, et al.
Published: (2022-12-01) -
The miR-205-5p/BRCA1/RAD17 Axis Promotes Genomic Instability in Head and Neck Squamous Cell Carcinomas
by: Fabio Valenti, et al.
Published: (2019-09-01) -
MYC Causes Multiple Myeloma Progression via Attenuating TP53-Induced MicroRNA-34 Expression
by: Yuki Murakami, et al.
Published: (2022-12-01) -
Microbe-Mediated Activation of Toll-like Receptor 2 Drives PDL1 Expression in HNSCC
by: Jacqueline E Mann, et al.
Published: (2021-09-01)